Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Warehousing Strategy at Volkswagen Group Canada Inc. (VGCA) - Teaching Note
P. Fraser Johnson; Adam BortolussiNota del Instructor IVEY-8B12D002-EServicios y operacionesTeaching note for product 9B12D002.Desde 0,00 €
-
Six Sigma at Cintas Corporation
P. Fraser Johnson; Adam BortolussiCaso IVEY-9B10D009-EServicios y operacionesThe green belt specialist at the Cintas Torlake facility near Toronto had four days before he was to present his recommendations to the executive steering committee (ESC) for correcting the capacity problem in the mat department, which was causing product shortages and negatively affecting customer satisfaction. The case provides data that students can use to analyze the processes used at the company for cleaning and replacing mats for its approx...Desde 8,20 €
-
Warehousing Strategy at Volkswagen Group Canada Inc. (VGCA)
P. Fraser Johnson; Adam BortolussiCaso IVEY-9B12D002-EServicios y operacionesThe director of warehousing and logistics at Volkswagen Group Canada (VGCA) had been tasked with analyzing the capacity of the Toronto parts distribution centre to support an aggressive growth plan that involved a series of new product launches and product facelifts. Expecting that expansion of the facility would be necessary, the director needed to determine the additional warehouse capacity required, when it would be needed by, and which expans...Desde 8,20 €
-
Celgene
Baker, Malcolm P.; McComb, Emily R.Caso HBS-218094-EFinanzasIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Desde 8,20 €
-
Celgene (B)
Baker, Malcolm P.; McComb, Emily R.Caso HBS-218099-EFinanzasIn February 2011, Adam Koppel, a Managing Director at Brookside Capital, the public equity arm of Bain Capital, must decide whether to increase or exit the firm's position in Celgene Corporation. News has emerged that raises potential safety concerns associated with Celgene's key drug, Revlimid. In response, Celgene's share price has traded down 20% in the last two months, and is now almost 10% below the level where Brookside made their initial i...Desde 5,74 €